Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy.
M C
MC
Van Aalderen
M C
MC
Trappenburg
M
M
Van Schilfgaarde
P J
PJ
Molenaar
H
H
Ten Cate
W E
WE
Terpstra
A
A
Leyte
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D055252:Cell-Derived Microparticles / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D042381:Granulocyte Precursor Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D013917:Thrombin / Q000378:metabolism*; D013927:Thrombosis / Q000097:blood / Q000209:etiology* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D013917:Thrombin